Digital Therapeutics in Urology: An Innovative Approach to Patient Care and Management

Area of Science:

• Digital Health
• Urology
• Health Informatics

Background:

• Digital therapeutics (DTx) are emerging as a novel class of evidence-based software interventions, gaining traction in neurology and psychiatry.
• The integration of DTx into urology practice remains largely unexplored, necessitating an assessment of patient readiness and infrastructure.
• Understanding patient expectations and the existing digital landscape is crucial for the successful implementation of DTx in urological care.

Purpose of the Study:

• To evaluate the potential of digital therapeutics (DTx) in urology by assessing patient adoption and infrastructure.
• To determine the prevalence of digital devices and applications among urology patients.
• To identify patient-desired features and requirements for the uptake of DTx in urological conditions.

Main Methods:

• An anonymized survey was conducted among patients with urologic conditions at two German academic centers.
• The survey, administered between November 2022 and January 2023, collected data on digital device ownership, app usage, and expectations for DTx.
• Statistical analysis compared digital infrastructure and app usage across different age groups (<65 yr vs. ≥65 yr).

Main Results:

• High prevalence of digital device ownership, including smartphones (93.6%), computers (80.4%), and tablets (51.7%), particularly among younger patients (<65 yr).
• Frequent use of general apps (95.6%) and health apps (57.6%) was observed, contrasting with low adoption of certified DTx apps (7.3%).
• Patients prioritize DTx solutions offering validated information (49.6%), data-driven medical advice (43.0%), and therapeutic support (41.7%).

Conclusions:

• Urology patients demonstrate significant digital literacy and app usage, indicating a receptive environment for digital therapeutics.
• Key requirements for DTx adoption include demonstrable therapeutic optimization (78.4%), positive health outcomes (76.9%), and enhanced patient autonomy (73.4%).
• Evolving regulatory and reimbursement landscapes suggest a growing role for DTx in urology, contingent on meeting patient-centric demands for efficacy and empowerment.